These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 33556340)

  • 1. TLR4/IL-6/IRF1 signaling regulates androgen receptor expression: A potential therapeutic target to overcome taxol resistance in ovarian cancer.
    Huang SL; Chang TC; Chao CCK; Sun NK
    Biochem Pharmacol; 2021 Apr; 186():114456. PubMed ID: 33556340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the TLR4-androgen receptor axis and genistein in taxol-resistant ovarian cancer cells.
    Huang SL; Chang TC; Chao CCK; Sun NK
    Biochem Pharmacol; 2020 Jul; 177():113965. PubMed ID: 32278794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TLR4 and NFκB signaling is critical for taxol resistance in ovarian carcinoma cells.
    Sun NK; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2018 Mar; 233(3):2489-2501. PubMed ID: 28771725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Integrative transcriptomics-based identification of cryptic drivers of taxol-resistance genes in ovarian carcinoma cells: Analysis of the androgen receptor.
    Sun NK; Huang SL; Lu HP; Chang TC; Chao CC
    Oncotarget; 2015 Sep; 6(29):27065-82. PubMed ID: 26318424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor transcriptional activity and chromatin modifications on the ABCB1/MDR gene are critical for taxol resistance in ovarian cancer cells.
    Sun NK; Kohli A; Huang SL; Chang TC; Chao CC
    J Cell Physiol; 2019 Jun; 234(6):8760-8775. PubMed ID: 30317630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptomic profiling of taxol-resistant ovarian cancer cells identifies FKBP5 and the androgen receptor as critical markers of chemotherapeutic response.
    Sun NK; Huang SL; Chang PY; Lu HP; Chao CC
    Oncotarget; 2014 Dec; 5(23):11939-56. PubMed ID: 25460502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H1.0 induces paclitaxel-resistance genes expression in ovarian cancer cells by recruiting GCN5 and androgen receptor.
    Kohli A; Huang SL; Chang TC; Chao CC; Sun NK
    Cancer Sci; 2022 Aug; 113(8):2616-2626. PubMed ID: 35639349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Galectin-3 induces ovarian cancer cell survival and chemoresistance via TLR4 signaling activation.
    Cai G; Ma X; Chen B; Huang Y; Liu S; Yang H; Zou W
    Tumour Biol; 2016 Sep; 37(9):11883-11891. PubMed ID: 27059733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of the MAD2-TLR4-MyD88 axis in paclitaxel resistance in ovarian cancer.
    Bates M; Spillane CD; Gallagher MF; McCann A; Martin C; Blackshields G; Keegan H; Gubbins L; Brooks R; Brooks D; Selemidis S; O'Toole S; O'Leary JJ
    PLoS One; 2020; 15(12):e0243715. PubMed ID: 33370338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-like growth factor 2 expression modulates Taxol resistance and is a candidate biomarker for reduced disease-free survival in ovarian cancer.
    Huang GS; Brouwer-Visser J; Ramirez MJ; Kim CH; Hebert TM; Lin J; Arias-Pulido H; Qualls CR; Prossnitz ER; Goldberg GL; Smith HO; Horwitz SB
    Clin Cancer Res; 2010 Jun; 16(11):2999-3010. PubMed ID: 20404007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
    Lee C
    Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.
    d'Adhemar CJ; Spillane CD; Gallagher MF; Bates M; Costello KM; Barry-O'Crowley J; Haley K; Kernan N; Murphy C; Smyth PC; O'Byrne K; Pennington S; Cooke AA; Ffrench B; Martin CM; O'Donnell D; Hennessy B; Stordal B; Finn S; McCann A; Gleeson N; D'Arcy T; Flood B; O'Neill LA; Sheils O; O'Toole S; O'Leary JJ
    PLoS One; 2014; 9(6):e100816. PubMed ID: 24977712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TLR4 signaling induced by lipopolysaccharide or paclitaxel regulates tumor survival and chemoresistance in ovarian cancer.
    Szajnik M; Szczepanski MJ; Czystowska M; Elishaev E; Mandapathil M; Nowak-Markwitz E; Spaczynski M; Whiteside TL
    Oncogene; 2009 Dec; 28(49):4353-63. PubMed ID: 19826413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways.
    Wang TH; Chan YH; Chen CW; Kung WH; Lee YS; Wang ST; Chang TC; Wang HS
    Oncogene; 2006 Aug; 25(35):4857-66. PubMed ID: 16547493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells.
    Suh YA; Jo SY; Lee HY; Lee C
    Int J Oncol; 2015 Mar; 46(3):1405-11. PubMed ID: 25544427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A BTB/POZ gene, NAC-1, a tumor recurrence-associated gene, as a potential target for Taxol resistance in ovarian cancer.
    Ishibashi M; Nakayama K; Yeasmin S; Katagiri A; Iida K; Nakayama N; Fukumoto M; Miyazaki K
    Clin Cancer Res; 2008 May; 14(10):3149-55. PubMed ID: 18483383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y; Niu XL; Qu Y; Wu J; Zhu YQ; Sun WJ; Li LZ
    Cancer Lett; 2010 Sep; 295(1):110-23. PubMed ID: 20236757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atractylenolide-I sensitizes human ovarian cancer cells to paclitaxel by blocking activation of TLR4/MyD88-dependent pathway.
    Huang JM; Zhang GN; Shi Y; Zha X; Zhu Y; Wang MM; Lin Q; Wang W; Lu HY; Ma SQ; Cheng J; Deng BF
    Sci Rep; 2014 Jan; 4():3840. PubMed ID: 24452475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Expression and significance of heparin binding-epidermal growth factor-like growth factor in paclitaxel-resistant ovarian cancer].
    Tang X; Lu M; Li C; Deng S; Li M
    Zhonghua Fu Chan Ke Za Zhi; 2014 Jul; 49(7):517-22. PubMed ID: 25327734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.